These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36123583)

  • 1. "Don't Think Twice, It's All Right": Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in England.
    Kang J; Cairns J
    Pharmacoecon Open; 2023 Jan; 7(1):77-91. PubMed ID: 36123583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
    Morrell L; Wordsworth S; Schuh A; Middleton MR; Rees S; Barker RW
    BMC Health Serv Res; 2018 May; 18(1):393. PubMed ID: 29855313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring uncertainty and use of real-world data in the National Institute for Health and Care Excellence single technology appraisals of targeted cancer therapy.
    Kang J; Cairns J
    BMC Cancer; 2022 Dec; 22(1):1268. PubMed ID: 36471259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cancer Drugs Fund in Practice and Under the New Framework.
    Sabry-Grant C; Malottki K; Diamantopoulos A
    Pharmacoeconomics; 2019 Jul; 37(7):953-962. PubMed ID: 30941698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for data extraction: how real-world data have been used in the National Institute for Health and Care Excellence appraisals of cancer therapy.
    Kang J; Cairns J
    BMJ Open; 2022 Jan; 12(1):e055985. PubMed ID: 34992121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective.
    Dunlop W; van Keep M; Elroy P; Perez ID; Ouwens MJNM; Sarbajna T; Zhang Y; Greystoke A
    Pharmacoecon Open; 2022 Mar; 6(2):241-252. PubMed ID: 34532842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process.
    Walton MJ; O'Connor J; Carroll C; Claxton L; Hodgson R
    Pharmacoecon Open; 2019 Sep; 3(3):403-410. PubMed ID: 30617953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.
    Aggarwal A; Fojo T; Chamberlain C; Davis C; Sullivan R
    Ann Oncol; 2017 Aug; 28(8):1738-1750. PubMed ID: 28453615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales.
    Chamberlain C; Collin SM; Stephens P; Donovan J; Bahl A; Hollingworth W
    Br J Cancer; 2014 Oct; 111(9):1693-702. PubMed ID: 24569469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary use of real-world data for clinical trial conduct in the United States: a scoping review.
    Rogers JR; Lee J; Zhou Z; Cheung YK; Hripcsak G; Weng C
    J Am Med Inform Assoc; 2021 Jan; 28(1):144-154. PubMed ID: 33164065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variance-based sensitivity analysis for uncertainties in proton therapy: A framework to assess the effect of simultaneous uncertainties in range, positioning, and RBE model predictions on RBE-weighted dose distributions.
    Hofmaier J; Dedes G; Carlson DJ; Parodi K; Belka C; Kamp F
    Med Phys; 2021 Feb; 48(2):805-818. PubMed ID: 33210739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.
    Wilkinson S; Gupta A; Scheuer N; Mackay E; Arora P; Thorlund K; Wasiak R; Ray J; Ramagopalan S; Subbiah V
    JAMA Netw Open; 2021 Oct; 4(10):e2126306. PubMed ID: 34618040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Tale of Two Thresholds: A Framework for Prioritization within the Cancer Drugs Fund.
    Leigh S; Granby P
    Value Health; 2016; 19(5):567-76. PubMed ID: 27565274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Data as External Controls: Practical Experience from Notable Marketing Applications of New Therapies.
    Izem R; Buenconsejo J; Davi R; Luan JJ; Tracy L; Gamalo M
    Ther Innov Regul Sci; 2022 Sep; 56(5):704-716. PubMed ID: 35676557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Assessment of Cancer Drugs Using Local Data Uploaded to the Systemic Anti-Cancer Therapy Dataset in England.
    Wadd N; Peedell C; Polwart C
    Clin Oncol (R Coll Radiol); 2022 Aug; 34(8):497-507. PubMed ID: 35584974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study.
    Boyle JM; Hegarty G; Frampton C; Harvey-Jones E; Dodkins J; Beyer K; George G; Sullivan R; Booth C; Aggarwal A
    Eur J Cancer; 2021 Sep; 155():136-144. PubMed ID: 34371443
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.